Stoke Therapeutics Liabilities 2024

Stoke Therapeutics Aktienanalyse

What does Stoke Therapeutics do?

Stoke Therapeutics Inc is a biopharmaceutical company founded in 2018 by experienced scientists to develop innovative therapeutic approaches for rare genetic diseases. The company's headquarters is located in Bedford, Massachusetts, and since its inception, it has continuously invested to expand its business and its development process. In 2019, the company announced a financing round of $90 million to advance the development of its pipeline and clinical trials. Stoke Therapeutics specializes in the development of therapeutics for the treatment of rare genetic diseases caused by mutations in haploinsufficiency genes. These diseases are caused by mutations in one of the two genes that code for a specific protein. Since a single defective gene is not sufficient to maintain the normal functions of a protein, serious health problems arise. Stoke's therapeutics aim to replace the missing gene product by targeted stimulation of the healthy gene. This is achieved through the development of antisense oligonucleotide-based therapeutics. Antisense oligonucleotides are small DNA-like molecules that are able to address, recognize, and bind to specific genes. By binding to the healthy gene, they can promote its expression and thereby replace the missing protein. The company's pipeline currently includes a range of products at various stages of development, including preclinical and clinical trials. The following products are the most important: STK-001: A product developed for the treatment of severe forms of Dravet syndrome. Dravet syndrome is a rare genetic disease characterized by seizures, developmental delays, and other neurological symptoms. STK-002: A product for the treatment of haploinsufficiency in STING1-associated vasculopathic syndrome (SAVS). SAVS is a rare genetic disease characterized by cardiovascular disorders and increased susceptibility to infections. STK-005: A product for the treatment of haploinsufficiency in adrenoleukodystrophy (ALD). ALD is a rare disease characterized by inflammatory and degenerative changes in the nervous system. Due to its innovative technology and focus on rare genetic diseases, Stoke Therapeutics has attracted the attention of many investors and potential partners. In 2020, the company entered into collaboration agreements with Roche Holdings and Ribometrix Inc to accelerate the development and commercialization of its therapeutics. Overall, Stoke Therapeutics has a promising future as it is able to provide a much-needed treatment option for patients with rare genetic diseases who currently have no effective therapies available. Stoke Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Stoke Therapeutics's Liabilities

Stoke Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Stoke Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Stoke Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Stoke Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Stoke Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Stoke Therapeutics stock

What is the level of liabilities of Stoke Therapeutics this year?

Stoke Therapeutics has a debt balance of 68.78 M USD this year.

What were the liabilities of Stoke Therapeutics compared to the previous year?

The liabilities of Stoke Therapeutics have increased by -3.4% dropped compared to the previous year.

What are the consequences of high debt for investors of Stoke Therapeutics?

High liabilities can pose a risk for investors of Stoke Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Stoke Therapeutics?

Low liabilities mean that Stoke Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Stoke Therapeutics affect the company?

An increase in liabilities of Stoke Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Stoke Therapeutics affect the company?

A decrease in the liabilities of Stoke Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Stoke Therapeutics?

Some factors that can influence the liabilities of Stoke Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Stoke Therapeutics so important for investors?

The liabilities of Stoke Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Stoke Therapeutics take to modify the liabilities?

To change its liabilities, Stoke Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Stoke Therapeutics pay?

Over the past 12 months, Stoke Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Stoke Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Stoke Therapeutics?

The current dividend yield of Stoke Therapeutics is .

When does Stoke Therapeutics pay dividends?

Stoke Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Stoke Therapeutics?

Stoke Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Stoke Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Stoke Therapeutics located?

Stoke Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Stoke Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Stoke Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Stoke Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Stoke Therapeutics in the year 2023?

In the year 2023, Stoke Therapeutics distributed 0 USD as dividends.

In which currency does Stoke Therapeutics pay out the dividend?

The dividends of Stoke Therapeutics are distributed in USD.